

**From:** [REDACTED]@sanofi.com>  
**Sent:** 29 July 2020 12:53  
**To:** [REDACTED] (SG-RECOVER); [REDACTED] (SG-RECOVER); [REDACTED]@pm.gouv.fr; [REDACTED] (SG); [REDACTED] (SANTE); GALLINA Sandra (SANTE); [REDACTED]@igf.finances.gouv.fr; [REDACTED] (SJ); [REDACTED] (SJ); [REDACTED]@gsk.com; [REDACTED]@gsk.com; [REDACTED]gsk.com; [REDACTED]  
**Cc:** [REDACTED]  
**Subject:** Confidential - Sanofi-GSK covid-19 vaccine TS 5  
**Attachments:** [REDACTED]

**Importance:** High

**To:** European Commission Negotiation Team

Dear EC Negotiation Team,

We looked into the revised version of our [REDACTED] and reached the conclusion that we are now very close to a definitive [REDACTED] and submit herewith our final offer.

In order to meet what we understood to be the two main concerns of the EC, we have adapted our final [REDACTED] according to the elements below:

[REDACTED]

[REDACTED]

We trust that these last adjustments will allow the European Commission to come to a final decision. Should the Commission confirm its interest by Friday, 31st July, Sanofi and GSK can start building industrial capacity in Europe as from now in order to be in a position to supply Member States with pandemic vaccine doses [REDACTED].

Sanofi and GSK remain available to provide any further explanation. We look forward to receiving your feedback.

Kind regards,

[REDACTED], on behalf of Sanofi and GSK

[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED] Brussels – Belgium  
EU Transparency Register: R1291462764-77  
[REDACTED] [\[REDACTED\]@sanofi.com](mailto:[REDACTED]@sanofi.com)

#Sanofi  
Acts

SANOFI 

Please consider the environment before printing this email

*This communication, including any attachments, is confidential and may be protected by law. If you are not the addressee, any use, disclosure, distribution, reproduction, copy or other dissemination of this communication is strictly prohibited. If you received this email in error, you must immediately notify the sender and then delete it. Sanofi Belgium accepts no liability for the incorrect and incomplete transfer of the information, nor for any delay or interruption of the transfer, nor for damage resulting from the use of or reliance on the information. All communications addressed to, received from or sent by Sanofi or Sanofi employees are considered to be of a professional nature. The sender or recipient agrees that they may be read by employees other than the official recipient or sender to ensure continuity. Personal data collected or generated during communication with Sanofi, including this message, will be processed by Sanofi based on our professional relationship with you, to manage this professional relationship, to comply with applicable legal obligations and, in some cases, to keep you informed of updates if you have consented or if we have a legitimate interest as a result of our relationship with you. You can exercise your access rights, right to rectification, deletion, limitation of processing and data portability, if applicable, and you can object to receiving updates from Sanofi by contacting the Data Protection Officer at [Dataprivacy.Belgium@sanofi.com](mailto:Dataprivacy.Belgium@sanofi.com). More information about Sanofi and its privacy policy is available at [www.sanofi.be](http://www.sanofi.be)*